Skip to main content

Table 4 Baseline characteristics in patients with different response to treatment

From: Comparations of efficacy and safety of rituximab, calcineurin inhibitors and cyclophosphamide in primary membranous nephropathy: a single-center retrospective analysis

Characteristic

Remission, n = 145

Non-remission, n = 113

p value

Age, yr

55 (45, 62)

57 (51, 67)

0.003

Male, n (%)

100 (69)

76 (67.3)

0.770

Systolic BP, mmHg

130 (113, 140)

131 (118.5, 142)

0.203

Diastolic BP, mmHg

79.65 ± 13.10

80.24 ± 15.44

0.089

Serum cholesterol, mmol/L

6.80 (5.48, 8.28)

6.89 (5.80, 8.64)

0.432

Serum creatinine, µmol/L

83 (68.5, 96.5)

80 (67, 92.5)

0.643

Serum albumin, g/L

24.9 ± 5.5

23.8 ± 4.9

0.227

eGFR, mL/min/1.73m2

90.6 (71.3, 101.8)

90.5 (72.7, 99.3)

0.609

UPCR, g/g

4.22 (3.53, 5.68)

4.24 (3.52, 5.28)

0.796

Anti-PLA2R-Ab-positive, n (%)a

100/124 (80.6)

67/79 (84.8)

0.449

Anti-PLA2R-Ab titer, RU/ml

41.10 (4.56, 110.63)

70.86 (22.26, 156.34)

0.015

ACE inhibitor/ARB use, n (%)

77 (53.1)

63 (55.8)

0.672

Treatment

  

0.008

CNI, n (%)

39 (26.9)

47 (41.6)

0.013

CTX, n (%)

47 (32.4)

39 (34.5)

0.723

RTX, n (%)

49 (40.7)

27 (23.9)

0.005

Prior immunosuppressive

therapy, n (%)

51 (35.2)

34 (30.1)

0.389

Follow-up, mo

15 (12, 24)

12 (6, 15)

< 0.001

  1. Data were shown as n (%), median (IQR) or mean ± SD. aA part of patients lack baseline anti-PLA2R-Ab tests, were shown as n/N. ACE, angiotensin-converting enzyme; ARB, angiotensin 2 receptor blocker; BP, blood pressure; CNI, calcineurin inhibitor; CTX, cyclophosphamide; eGFR, estimated glomerular filtration rate; anti-PLA2R-Ab, anti-M-type phospholipase A2 receptor antibody; RTX, rituximab; UPCR, urine protein-to-creatinine ratio